Tesamorelin in District 1: What Product Identity and Storage Documentation Can—and Cannot—Prove

Executive Brief

A Certificate of Analysis (CoA), product label, laboratory report, and storage log can each provide useful evidence about tesamorelin. However, they answer different questions. Identity testing evaluates whether a tested sample is consistent with the claimed substance. Assay testing measures a specified component. Purity testing characterizes detected components under a particular method. Storage records document monitored environmental conditions, while stability studies evaluate how defined quality attributes change over time.

These forms of evidence are complementary, not interchangeable. A high purity percentage does not prove the labelled quantity. A matching identity result does not establish sterility. A temperature log does not directly demonstrate chemical stability. Even a complete-looking CoA does not independently establish that the report is authentic, that the sample represents the entire batch, or that the product is authorized for human use.

For readers researching tesamorelin in District 1, Ho Chi Minh City, the most useful approach is to match each product claim to the type of evidence capable of supporting it—and recognize what remains unverified.

1. Why Product Documentation Matters for Tesamorelin

Tesamorelin is a synthetic peptide analogue of growth hormone-releasing hormone. Specific tesamorelin formulations have been approved in the United States for reducing excess abdominal fat in adults with HIV-associated lipodystrophy. That regulatory history applies to the relevant approved products and does not establish the quality, equivalence, or authorization of every product marketed under the name tesamorelin.

This distinction matters when evaluating products described as “research grade,” “research use only,” or similar terms. Such wording is not, by itself, evidence of pharmaceutical-grade manufacturing, sterility, clinical effectiveness, or authorization for human use.

Documentation can help establish what a supplier claims to provide, which tests were reported, and how material was handled. Its value depends on the quality of the underlying evidence, the identity of the tested sample, and the scope of the conclusions being drawn.

For foundational background, readers can explore the Vietnam Peptides Knowledge Hub and the Peptide FAQ on Research, Storage, and Usage Questions.

2. What Does Tesamorelin Identity Testing Actually Prove?

Identity testing evaluates whether the material tested is consistent with the claimed substance. For peptides, analytical characterization may involve techniques that provide information about molecular mass, chromatographic behaviour, sequence-related characteristics, or other relevant chemical attributes.

The appropriate method depends on the analytical question, the properties of the material, and the applicable specification. FDA guidance aligned with ICH Q6A explains that identity testing should be sufficiently specific to distinguish the intended substance from relevant alternatives. It also states that identification based solely on a single chromatographic retention time is not sufficiently specific.

Depending on the material and analytical purpose, methods may include liquid chromatography coupled with mass spectrometry (LC-MS), suitable spectroscopic techniques, or complementary analytical procedures. The presence of one method name on a report does not automatically establish that the method was suitable, validated for its intended purpose, or interpreted correctly.

What an identity result can support

• The tested sample showed analytical characteristics consistent with the claimed substance under the method used.
• The result met a defined identity criterion, where the criterion and method are appropriate.
• The findings can be compared with a suitable reference or expected analytical characteristics, when such a reference is available and relevant.

What an identity result cannot establish by itself

• That every vial in a batch has the same identity or quality as the tested sample.
• That the vial contains the labelled amount of tesamorelin.
• That all relevant impurities, degradation products, residual solvents, or process-related contaminants have been detected and controlled.
• That the material is sterile, has acceptable endotoxin levels, or is suitable for injection.
• That the sample genuinely originated from the manufacturer or batch stated on the label.

3. Identity, Purity, Assay, and Strength Are Not Synonyms

Product documentation sometimes presents identity, purity, assay, and strength as though they describe the same attribute. They do not. Confusing these terms can lead readers to draw conclusions that the reported data do not support.

Identity concerns whether the material is consistent with the claimed substance. Purity often describes the distribution of detected components under a particular analytical method. Assay is intended to quantify a specified component using an appropriate procedure. Strength or content refers to the amount of the specified active component in the relevant unit or formulation, as defined by the applicable specification.

For example, a chromatographic method may show that the principal detected peak accounts for a high percentage of the integrated signal. That result does not automatically establish the total mass of tesamorelin in a vial. The conclusion depends on the method, detector response, calibration, integration, and the substances the procedure can detect.

Nor does a high principal-peak percentage prove that every potentially relevant impurity is absent. Some substances may not be detected adequately by a given method, and some impurities may require separate procedures or acceptance criteria.

The FDA’s ICH Q6A guidance provides a framework for pharmaceutical specifications, identity testing, assay, and other quality attributes. The central principle is that each quality claim should be supported by a suitable test and defined acceptance criteria.

4. How to Evaluate a Certificate of Analysis (CoA)

A Certificate of Analysis records specified test results for an identified material or batch. FDA’s ICH Q7 guidance describes expectations for CoAs associated with active pharmaceutical ingredients, including material identification, batch number, relevant tests, acceptance limits, numerical results where applicable, and appropriate issuer details.

A CoA is not automatically reliable because it looks professional or contains a laboratory logo. The document’s authenticity, the laboratory’s role, the appropriateness of the methods, and the link between the tested sample and the product under review all matter.

Key fields to examine

• Material name and description: The claimed substance should be identified clearly, with relevant form or grade information where applicable.
• Batch or lot number: The identifier should be consistent with the product and supporting records.
• Test methods: The report should identify the procedures used or provide enough detail to assess their relevance.
• Acceptance criteria: Specifications or limits should be stated, rather than relying only on an unexplained “pass” result.
• Actual results: Numerical results and units, where applicable, make the findings easier to evaluate.
• Laboratory and manufacturer details: The document should make clear who performed the analysis and who manufactured or repackaged the material.
• Dates and authorization: Relevant test dates, issue dates, and authorized approval help establish the record’s context.
• Sample traceability: The report should be linked to a defined sample and the batch or material it is intended to represent.

A CoA may be issued by the manufacturer or by a third-party laboratory. A third-party report can provide useful independent evidence, but independence alone does not prove that the tested sample came from the claimed batch or that the report is authentic.

Likewise, laboratory accreditation can support confidence in competence for the activities within its scope. It does not establish that every test in every report is valid, that the sample is representative, or that the product meets requirements that were never tested.

5. Batch Traceability: Does the Report Belong to the Product?

Even technically sound analytical results have limited value if they cannot be linked to the product being assessed. A report may describe a sample accurately while leaving unanswered whether that sample came from the labelled batch, whether the product was repackaged, or whether the report relates to the current lot.

Traceability involves the relationship between the product label, batch number, CoA, sample records, manufacturing or packaging records, and relevant transport or storage documentation.

Questions that help clarify the evidence include:

• Does the batch number on the label match the batch number in the CoA?
• Does the report identify the original manufacturer and the testing organization, where relevant?
• Is it clear what material was tested and how the sample was identified?
• Can the issuing laboratory or manufacturer confirm the report’s authenticity?
• Are repackaging, relabelling, or transfers between organizations documented where applicable?
• Does the report cover the actual batch being assessed, rather than a different lot or a representative sample whose relationship to the product is unclear?

A batch number printed on both a vial and a report is a useful consistency check, but it is not independent proof that the two items are genuinely connected. Reliable traceability requires a credible record linking the sample, report, and product.

6. What Storage Logs Can—and Cannot—Show

Storage records can be important because peptide materials may be affected by temperature, moisture, light, time, formulation, packaging, and other environmental or handling factors. The significance of each factor depends on the specific substance and product system.

A temperature log documents readings from a monitoring system over a defined period. If the monitoring device, recordkeeping process, and monitoring coverage are appropriate, the log can help establish whether the recorded conditions remained within a specified range.

However, a temperature log does not directly measure chemical degradation, peptide content, aggregation, moisture uptake, or potency. It may also have gaps, cover only part of the supply chain, or record conditions at the sensor location rather than the exact conditions experienced by every container.

Useful elements of storage documentation

• Clearly defined storage requirements applicable to the actual product and formulation.
• Records identifying the monitored location and the period covered.
• Identifiable monitoring equipment and relevant calibration or qualification records.
• Documented handling of temperature excursions or other deviations.
• Traceability between the storage records and the batch or shipment under review.
• Relevant stability data supporting the proposed storage period and conditions.

A statement that a product was “stored correctly” should therefore be evaluated against the specified conditions, the completeness and reliability of the records, and evidence that those conditions are appropriate for that particular product.

7. Why Stability Studies Are Different from Storage Records

Stability is not established merely by showing that a product was kept within a stated temperature range. Stability studies evaluate how defined quality attributes change over time under specified environmental conditions. For pharmaceutical products, those studies can support retest periods for drug substances, shelf life for drug products, and recommended storage conditions.

The relevant attributes depend on the product and its risks. They may include appearance, assay, degradation products, physical properties, or other chemical and microbiological measures. The study design and acceptance criteria should be appropriate to the substance, formulation, packaging system, and intended regulatory purpose.

The ICH Q1A(R2) guidance describes the role of stability testing in evaluating changes in drug substances and products over time. In June 2025, the FDA also published a draft consolidated ICH Q1 guidance; because that document is a draft, it should not be described as final or as replacing applicable final guidance without checking its regulatory status.

A general supplier statement such as “stable under refrigeration” is not equivalent to a stability study for the exact material. To assess the claim, readers need to understand which product and formulation were tested, the packaging used, the conditions and duration studied, the attributes measured, and the criteria applied.

Stability data for one tesamorelin formulation should not automatically be transferred to a different formulation, manufacturing process, container, or product marketed under the same peptide name.

8. What Approved Tesamorelin Labels Tell Us About Storage

Official U.S. prescribing information for EGRIFTA SV and EGRIFTA WR illustrates why storage instructions must be tied to the exact product rather than generalized across all materials called tesamorelin.

The EGRIFTA SV label describes a 2 mg lyophilized-powder vial and specifies storage at 20°C to 25°C, with permitted excursions to 15°C to 30°C, protected from light in the original box. Its handling instructions are specific to that formulation and presentation.

The EGRIFTA WR label describes a different presentation, including an 11.6 mg vial and a different diluent arrangement. It also has product-specific storage and handling instructions. The official labeling explicitly states that EGRIFTA WR and EGRIFTA SV are not substitutable.

These examples establish an important principle: even approved products containing the same active ingredient may differ in formulation, packaging, preparation requirements, and labelled handling instructions. The official label for one product cannot be treated as a universal storage specification for unrelated research-labelled materials.

For a regulated medicine, consult the current official label for the exact product. For a research-labelled material, the approved medicine’s storage instructions do not establish that the research product has the same stability, quality, or suitability.

9. Product Quality, Regulatory Authorization, and Human-Use Suitability

Product quality, regulatory status, and clinical suitability are distinct questions. Documentation that supports one does not automatically resolve the others.

A laboratory report does not establish marketing authorization. Likewise, the existence of an approved tesamorelin medicine in the United States does not mean that every tesamorelin-labelled product is approved in the United States or Vietnam.

Readers evaluating tesamorelin in District 1 or elsewhere in Vietnam should verify the regulatory status of the specific product through relevant official sources. The active ingredient name, an online listing, a batch number, or a CoA cannot independently establish local authorization.

10. Evidence Snapshot: What the Main Sources Support

The table below summarizes the scope of several relevant official sources. It does not rate or certify any particular supplier, batch, or product.

11. A Practical Framework for Reviewing Product Evidence

A disciplined review can be organized around five questions:

1. Identity: Does the analytical method adequately support the claimed substance, and is the result linked to the sample being assessed?
2. Quantity and impurities: Are assay, purity, and impurity claims supported by appropriate methods, actual results, and defined acceptance criteria?
3. Traceability: Can the report be connected reliably to the stated batch, manufacturer, and product?
4. Storage and stability: Are recorded conditions complete and credible, and is there relevant stability evidence for the material and packaging?
5. Regulatory status: Is the specific product’s authorization established through the relevant official source, rather than inferred from a compound name or laboratory report?

The key principle is to avoid using one positive result as proof of unrelated attributes. Each claim should be supported by evidence that actually addresses that claim.

For more context on peptide research and product categories, visit the Knowledge Hub, the Peptide FAQ, and the Peptide Products and Research page. These educational resources should complement official product information and applicable regulatory guidance.

12. Frequently Asked Questions

13. Related Research Products

14. Scientific References

1. U.S. Food and Drug Administration (FDA). ICH Q6A: Specifications—Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substances. Read the official guidance.
2. U.S. Food and Drug Administration (FDA). ICH Q7: Good Manufacturing Practice Guidance for Active Pharmaceutical Ingredients. Includes expectations for CoAs, batch documentation, analytical controls, and quality records. Read the official guidance.
3. International Council for Harmonisation (ICH) / FDA. Q1A(R2): Stability Testing of New Drug Substances and Products. Guidance on stability studies, retest periods, shelf life, and storage conditions. Read the official guidance.
4. U.S. Food and Drug Administration (FDA). Q1 Stability Testing of Drug Substances and Drug Products. Consolidated draft guidance published in June 2025; draft status should be noted when citing it. Read the draft guidance notice.
5. DailyMed / U.S. National Library of Medicine. EGRIFTA SV (tesamorelin) for injection: official prescribing information and product-specific storage and handling requirements. Read the EGRIFTA SV label.
6. DailyMed / U.S. National Library of Medicine. EGRIFTA WR (tesamorelin) for injection: official prescribing information, product presentation, and storage and handling requirements. Read the EGRIFTA WR label.

Conclusion

Product identity and storage documentation are important evidence for tesamorelin, but their conclusions must remain within the limits of what each record actually measures. Identity testing supports a claim about a tested sample. A CoA reports defined results against specified criteria. Storage logs document monitored environmental conditions. Stability studies evaluate quality changes over time under defined conditions.

Reliable assessment depends on connecting those forms of evidence through suitable analytical methods, authentic records, batch traceability, and stability data relevant to the actual material and packaging. No single certificate, purity percentage, or storage statement can replace that broader assessment.

For anyone researching tesamorelin in District 1 or elsewhere in Vietnam, the most defensible approach is to distinguish what has been measured, what the documentation supports, and what remains unproven. That approach supports clearer scientific reasoning without overstating product quality or implying regulatory and clinical claims that the evidence does not establish.